Take Solutions Ltd
Incorporated in 2000, TAKE Solutions Ltd is in the business of Life Sciences and Support Services[1]
- Market Cap ₹ 349 Cr.
- Current Price ₹ 23.5
- High / Low ₹ 35.8 / 15.1
- Stock P/E
- Book Value ₹ 6.89
- Dividend Yield 0.00 %
- ROCE -14.0 %
- ROE -62.5 %
- Face Value ₹ 1.00
Pros
- Company has reduced debt.
- Debtor days have improved from 103 to 58.0 days.
- Company's working capital requirements have reduced from 118 days to 20.4 days
Cons
- Stock is trading at 3.42 times its book value
- Company has low interest coverage ratio.
- The company has delivered a poor sales growth of -34.7% over past five years.
- Company has a low return on equity of -51.5% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Miscellaneous Industry: Miscellaneous
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
704 | 832 | 816 | 730 | 1,030 | 1,345 | 1,587 | 2,039 | 2,213 | 774 | 655 | 189 | 90 | |
559 | 670 | 668 | 581 | 817 | 1,082 | 1,281 | 1,655 | 2,044 | 847 | 648 | 208 | 77 | |
Operating Profit | 145 | 161 | 147 | 149 | 213 | 262 | 307 | 384 | 169 | -73 | 7 | -19 | 13 |
OPM % | 21% | 19% | 18% | 20% | 21% | 20% | 19% | 19% | 8% | -9% | 1% | -10% | 14% |
15 | 7 | 6 | 8 | 21 | 13 | 6 | 11 | 26 | -211 | -677 | -56 | -58 | |
Interest | 18 | 14 | 14 | 13 | 15 | 23 | 21 | 25 | 41 | 37 | 29 | 7 | 8 |
Depreciation | 27 | 46 | 77 | 60 | 74 | 87 | 104 | 154 | 167 | 115 | 80 | 17 | 11 |
Profit before tax | 115 | 107 | 63 | 85 | 145 | 165 | 188 | 216 | -13 | -437 | -779 | -99 | -64 |
Tax % | 18% | 17% | 2% | 6% | 14% | 11% | 15% | 17% | 15% | -3% | -0% | -2% | |
94 | 89 | 62 | 80 | 125 | 146 | 160 | 178 | -11 | -450 | -782 | -100 | -65 | |
EPS in Rs | 6.99 | 6.49 | 4.74 | 5.71 | 9.78 | 10.74 | 10.85 | 11.99 | -0.84 | -30.56 | -52.88 | -6.78 | -4.38 |
Dividend Payout % | 14% | 15% | 21% | 17% | 10% | 9% | 15% | 8% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | -14% |
5 Years: | -35% |
3 Years: | -56% |
TTM: | -53% |
Compounded Profit Growth | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | % |
TTM: | 86% |
Stock Price CAGR | |
---|---|
10 Years: | -3% |
5 Years: | -31% |
3 Years: | -22% |
1 Year: | 52% |
Return on Equity | |
---|---|
10 Years: | -5% |
5 Years: | -18% |
3 Years: | -51% |
Last Year: | -62% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 12 | 12 | 12 | 12 | 12 | 13 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
Reserves | 330 | 408 | 458 | 512 | 619 | 898 | 1,314 | 1,504 | 1,561 | 1,110 | 166 | 94 | 87 |
193 | 196 | 207 | 209 | 336 | 237 | 323 | 474 | 553 | 514 | 59 | 46 | 43 | |
206 | 220 | 185 | 189 | 246 | 221 | 189 | 339 | 336 | 187 | 984 | 69 | 69 | |
Total Liabilities | 741 | 837 | 862 | 922 | 1,214 | 1,369 | 1,840 | 2,331 | 2,465 | 1,826 | 1,223 | 224 | 214 |
339 | 368 | 384 | 359 | 543 | 554 | 589 | 1,091 | 1,234 | 934 | 101 | 73 | 86 | |
CWIP | 1 | 3 | 2 | 17 | 3 | 21 | 42 | 41 | 1 | 0 | 3 | 11 | 0 |
Investments | 50 | 50 | 50 | 6 | 21 | 10 | 59 | 10 | 18 | 7 | 0 | 0 | 0 |
351 | 415 | 426 | 541 | 647 | 785 | 1,150 | 1,188 | 1,213 | 885 | 1,119 | 140 | 127 | |
Total Assets | 741 | 837 | 862 | 922 | 1,214 | 1,369 | 1,840 | 2,331 | 2,465 | 1,826 | 1,223 | 224 | 214 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
115 | 117 | 100 | 74 | 151 | 56 | 121 | 104 | 211 | 135 | 30 | 20 | |
-81 | -70 | -91 | -14 | -292 | -130 | -179 | -474 | -233 | -57 | 15 | -3 | |
-21 | -31 | -7 | -11 | 111 | 56 | 302 | 100 | 21 | -84 | -55 | -36 | |
Net Cash Flow | 13 | 16 | 2 | 49 | -30 | -18 | 243 | -270 | -2 | -6 | -10 | -18 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 82 | 99 | 100 | 120 | 107 | 118 | 108 | 94 | 116 | 205 | 45 | 58 |
Inventory Days | ||||||||||||
Days Payable | ||||||||||||
Cash Conversion Cycle | 82 | 99 | 100 | 120 | 107 | 118 | 108 | 94 | 116 | 205 | 45 | 58 |
Working Capital Days | 55 | 71 | 83 | 121 | 107 | 136 | 143 | 142 | 137 | 289 | 45 | 20 |
ROCE % | 25% | 20% | 11% | 13% | 16% | 17% | 15% | 13% | 1% | -9% | -6% | -14% |
Documents
Announcements
-
Compliance Certificate For The Year Ended March 31, 2024
15 Apr - Compliance Certificate pursuant to Regulation 7(3) of SEBI (LODR) Regulations, 2015 for the year ended March 31, 2024
- Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 15 Apr
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
10 Apr - Certificate pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2024
- Corrigendum To Summary Of Proceedings Of The Twenty Second Annual General Meeting 8 Apr
- Disclosure Under Regulation 31(4)Of SEBI (Substantial Acquisition Of Shares And Takeover) Regulation, 2011 5 Apr
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
Concalls
-
Aug 2021TranscriptPPT
-
Jun 2021TranscriptPPT
-
Feb 2021TranscriptPPT
-
Dec 2020TranscriptPPT
-
Sep 2020TranscriptPPT
-
Oct 2019TranscriptPPT
-
Aug 2019TranscriptPPT
-
May 2019TranscriptPPT
-
Mar 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Feb 2019TranscriptPPT
-
Aug 2018TranscriptPPT
-
May 2018TranscriptPPT
-
Feb 2018TranscriptPPT
-
Nov 2017TranscriptPPT
-
Nov 2017TranscriptPPT
-
Aug 2017TranscriptPPT
-
May 2017TranscriptPPT
-
Jan 2017TranscriptPPT
-
Dec 2016TranscriptPPT
-
Oct 2016TranscriptPPT
-
Feb 2016TranscriptNotesPPT
Business Overview:[1]
Singapore-based TAKE Solutions Pte Limited holds a 52.90% stake in TSL, serving as the holding company. TSL specializes in Life Sciences and Supply Chain Management, providing comprehensive services in clinical development and specific offerings in supply chain. The company is involved in clinical trials, generics support, including bio-availability & bioequivalent studies, regulatory filing, and pharmacovigilance.